{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T16:16:08Z","timestamp":1790612168121,"version":"4.1.0"},"reference-count":171,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2013,4,1]],"date-time":"2013-04-01T00:00:00Z","timestamp":1364774400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cytokine & Growth Factor Reviews"],"published-print":{"date-parts":[[2013,4]]},"DOI":"10.1016\/j.cytogfr.2013.01.004","type":"journal-article","created":{"date-parts":[[2013,2,13]],"date-time":"2013-02-13T17:15:49Z","timestamp":1360775749000},"page":"133-145","source":"Crossref","is-referenced-by-count":142,"title":["The role of cytokines in the initiation and progression of myelofibrosis"],"prefix":"10.1016","volume":"24","author":[{"given":"Hans C.","family":"Hasselbalch","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"Suppl. 1","key":"10.1016\/j.cytogfr.2013.01.004_bib0005","doi-asserted-by":"crossref","first-page":"S34","DOI":"10.1002\/eji.200737772","article-title":"Historical insights into cytokines","volume":"37","author":"Dinarello","year":"2007","journal-title":"European Journal of Immunology"},{"key":"10.1016\/j.cytogfr.2013.01.004_bib0010","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.ajpath.2010.08.003","article-title":"Wound macrophages as key regulators of repair: origin, phenotype, and function","volume":"178","author":"Brancato","year":"2011","journal-title":"American Journal of Pathology"},{"key":"10.1016\/j.cytogfr.2013.01.004_bib0015","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1189\/jlb.0409236","article-title":"The phenotype of murine wound macrophages","volume":"87","author":"Daley","year":"2010","journal-title":"Journal of Leukocyte Biology"},{"key":"10.1016\/j.cytogfr.2013.01.004_bib0020","doi-asserted-by":"crossref","first-page":"349","DOI":"10.12968\/jowc.2009.18.8.43636","article-title":"Role of macrophages in normal wound healing: an overview","volume":"18","author":"Adamson","year":"2009","journal-title":"Journal of Wound Care"},{"key":"10.1016\/j.cytogfr.2013.01.004_bib0025","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1177\/0022034509359125","article-title":"Factors affecting wound healing","volume":"89","author":"Guo","year":"2010","journal-title":"Journal of Dental Research"},{"key":"10.1016\/j.cytogfr.2013.01.004_bib0030","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1007\/s00268-003-7397-6","article-title":"Aging and wound healing","volume":"28","author":"Gosain","year":"2004","journal-title":"World Journal of Surgery"},{"key":"10.1016\/j.cytogfr.2013.01.004_bib0035","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1152\/physrev.2003.83.3.835","article-title":"Regulation of wound healing by growth factors and cytokines","volume":"83","author":"Werner","year":"2003","journal-title":"Physiological Reviews"},{"key":"10.1016\/j.cytogfr.2013.01.004_bib0040","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1016\/j.cell.2010.01.025","article-title":"Immunity, inflammation, and cancer","volume":"140","author":"Grivennikov","year":"2010","journal-title":"Cell"},{"key":"10.1016\/j.cytogfr.2013.01.004_bib0045","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1056\/NEJM198612253152606","article-title":"Tumors: wounds that do not heal. Similarities between tumor stroma generation and wound healing","volume":"315","author":"Dvorak","year":"1986","journal-title":"New England Journal of Medicine"},{"key":"10.1016\/j.cytogfr.2013.01.004_bib0050","doi-asserted-by":"crossref","first-page":"3267","DOI":"10.4161\/cc.8.20.9699","article-title":"Inflammation: a driving force speeds cancer metastasis","volume":"8","author":"Wu","year":"2009","journal-title":"Cell Cycle"},{"key":"10.1016\/j.cytogfr.2013.01.004_bib0055","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1038\/nrc1256","article-title":"Tumour-educated macrophages promote tumour progression and metastasis","volume":"4","author":"Pollard","year":"2004","journal-title":"Nature Reviews Cancer"},{"key":"10.1016\/j.cytogfr.2013.01.004_bib0060","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1007\/978-0-387-69116-9_5","article-title":"Tumor promotion by tumor-associated macrophages","volume":"604","author":"Porta","year":"2007","journal-title":"Advances in Experimental Medicine and Biology"},{"key":"10.1016\/j.cytogfr.2013.01.004_bib0065","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1007\/978-1-60327-530-9_18","article-title":"Investigating macrophage and malignant cell interactions in vitro","volume":"512","author":"Hagemann","year":"2009","journal-title":"Methods in Molecular Biology"},{"key":"10.1016\/j.cytogfr.2013.01.004_bib0070","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1126\/science.306.5698.966","article-title":"Cancer research. Inflammation and cancer: the link grows stronger","volume":"306","author":"Marx","year":"2004","journal-title":"Science"},{"key":"10.1016\/j.cytogfr.2013.01.004_bib0075","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1038\/nri1703","article-title":"NF-\u03baB: linking inflammation and immunity to cancer development and progression","volume":"5","author":"Karin","year":"2005","journal-title":"Nature Reviews Immunology"},{"key":"10.1016\/j.cytogfr.2013.01.004_bib0080","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1111\/j.1600-065X.2012.01099.x","article-title":"NF-\u03baB and the link between inflammation and cancer","volume":"246","author":"DiDonato","year":"2012","journal-title":"Immunological Reviews"},{"key":"10.1016\/j.cytogfr.2013.01.004_bib0085","doi-asserted-by":"crossref","first-page":"2452","DOI":"10.1056\/NEJMra063728","article-title":"The myeloproliferative disorders","volume":"355","author":"Campbell","year":"2006","journal-title":"New England Journal of Medicine"},{"key":"10.1016\/j.cytogfr.2013.01.004_bib0090","article-title":"Chronic inflammation as a promoter of mutagenesis in essential thrombocythemia, polycythemia vera and myelofibrosis. A human inflammation model for cancer development?","author":"Hasselbalch","year":"2012","journal-title":"Leukemia Research"},{"key":"10.1016\/j.cytogfr.2013.01.004_bib0095","doi-asserted-by":"crossref","first-page":"3219","DOI":"10.1182\/blood-2011-11-394775","article-title":"Perspectives on chronic inflammation in essential thrombocythemia, polycythemia vera, and myelofibrosis: is chronic inflammation a trigger and driver of clonal evolution and development of accelerated atherosclerosis and second cancer?","volume":"119","author":"Hasselbalch","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.cytogfr.2013.01.004_bib0100","doi-asserted-by":"crossref","first-page":"3472","DOI":"10.1182\/blood-2006-04-018879","article-title":"MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients","volume":"108","author":"Pardanani","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.cytogfr.2013.01.004_bib0105","doi-asserted-by":"crossref","first-page":"2289","DOI":"10.1056\/NEJMoa0810069","article-title":"Mutation in TET2 in myeloid cancers","volume":"360","author":"Delhommeau","year":"2009","journal-title":"New England Journal of Medicine"},{"key":"10.1016\/j.cytogfr.2013.01.004_bib0110","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1038\/ng.621","article-title":"Inactivating mutations of the histone methyltransferase gene EZH2 in myeloid disorders","volume":"42","author":"Ernst","year":"2010","journal-title":"Nature Genetics"},{"key":"10.1016\/j.cytogfr.2013.01.004_bib0115","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1038\/leu.2010.69","article-title":"Novel mutations and their functional and clinical relevance in myeloproliferative neoplasms: JAK2, MPL, TET2, ASXL1, CBL, IDH and IKZF1","volume":"24","author":"Tefferi","year":"2010","journal-title":"Leukemia"},{"key":"10.1016\/j.cytogfr.2013.01.004_bib0120","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1182\/blood-2010-02-270108","article-title":"Novel mutations in the inhibitory adaptor protein LNK drive JAK\u2013STAT signaling in patients with myeloproliferative neoplasms","volume":"116","author":"Oh","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.cytogfr.2013.01.004_bib0125","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1182\/blood-2011-01-331678","article-title":"Genome integrity of myeloproliferative neoplasms in chronic phase and during disease progression","volume":"118","author":"Klampfl","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.cytogfr.2013.01.004_bib0130","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1002\/ajh.22166","article-title":"Identification of genomic aberrations associated with disease transformation by means of high-resolution SNP array analysis in patients with myeloproliferative neoplasm","volume":"86","author":"Rumi","year":"2011","journal-title":"American Journal of Hematology"},{"key":"10.1016\/j.cytogfr.2013.01.004_bib0135","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1111\/j.1600-0609.2011.01618.x","article-title":"Whole-blood transcriptional profiling of interferon-inducible genes identifies highly upregulated IFI27 in primary myelofibrosis","volume":"87","author":"Skov","year":"2011","journal-title":"European Journal of Haematology"},{"issue":"11","key":"10.1016\/j.cytogfr.2013.01.004_bib0140","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1016\/j.leukres.2012.07.009","article-title":"Molecular profiling of peripheral blood cells from patients with polycythemia vera and related neoplasms: identification of deregulated genes of significance for inflammation and immune surveillance","volume":"36","author":"Skov","year":"2012","journal-title":"Leukemia Research"},{"issue":"9","key":"10.1016\/j.cytogfr.2013.01.004_bib0145","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1016\/j.exphem.2012.05.011","article-title":"Gene expression profiling with principal component analysis depicts the biological continuum from essential thrombocythemia over polycythemia vera to myelofibrosis","volume":"40","author":"Skov","year":"2012","journal-title":"Experimental Hematology"},{"key":"10.1016\/j.cytogfr.2013.01.004_bib0150","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1200\/JCO.2010.32.9490","article-title":"Circulating interleukin (IL)-8, IL-2R, IL-12, and IL-15 levels are independently prognostic in primary myelofibrosis: a comprehensive cytokine profiling study","volume":"29","author":"Tefferi","year":"2011","journal-title":"Journal of Clinical Oncology"},{"issue":"11","key":"10.1016\/j.cytogfr.2013.01.004_bib0155","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1002\/ajh.23295","article-title":"Plasma cytokines in polycythemia vera: phenotypic correlates, prognostic relevance, and comparison with myelofibrosis","volume":"87","author":"Vaidya","year":"2012","journal-title":"American Journal of Hematology"},{"key":"10.1016\/j.cytogfr.2013.01.004_bib0160","doi-asserted-by":"crossref","first-page":"2623","DOI":"10.4049\/jimmunol.178.5.2623","article-title":"The JAK\u2013STAT signaling pathway: input and output integration","volume":"178","author":"Murray","year":"2007","journal-title":"Journal of Immunology"},{"key":"10.1016\/j.cytogfr.2013.01.004_bib0165","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.semcdb.2008.08.010","article-title":"Interferons pen the JAK\u2013STAT pathway","volume":"19","author":"Schindler","year":"2008","journal-title":"Seminars in Cell and Developmental Biology"},{"key":"10.1016\/j.cytogfr.2013.01.004_bib0170","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/S0092-8674(00)81166-6","article-title":"Disruption of the Jak1 gene demonstrates obligatory and nonredundant roles of the Jaks in cytokine-induced biologic responses","volume":"93","author":"Rodig","year":"1998","journal-title":"Cell"},{"key":"10.1016\/j.cytogfr.2013.01.004_bib0175","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/S0092-8674(00)81168-X","article-title":"Jak2 deficiency defines an essential developmental checkpoint in definitive hematopoiesis","volume":"93","author":"Neubauer","year":"1998","journal-title":"Cell"},{"key":"10.1016\/j.cytogfr.2013.01.004_bib0180","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/S0092-8674(00)81167-8","article-title":"Jak2 is essential for signaling through a variety of cytokine receptors","volume":"93","author":"Parganas","year":"1998","journal-title":"Cell"},{"key":"10.1016\/j.cytogfr.2013.01.004_bib0185","doi-asserted-by":"crossref","first-page":"3109","DOI":"10.1182\/blood-2009-04-214957","article-title":"Preclinical characterization of the selective JAK1\/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms","volume":"115","author":"Quintas-Cardama","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.cytogfr.2013.01.004_bib0190","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1038\/nrc2210","article-title":"Role of JAK2 in the pathogenesis and therapy of myeloproliferative disorders","volume":"7","author":"Levine","year":"2007","journal-title":"Nature Reviews Cancer"},{"key":"10.1016\/j.cytogfr.2013.01.004_bib0195","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/j.semcdb.2008.07.002","article-title":"JAKs in pathology: role of Janus kinases in hematopoietic malignancies and immunodeficiencies","volume":"19","author":"Vainchenker","year":"2008","journal-title":"Seminars in Cell and Developmental Biology"},{"key":"10.1016\/j.cytogfr.2013.01.004_bib0200","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/S0092-8674(00)81288-X","article-title":"Targeted disruption of the Stat1 gene in mice reveals unexpected physiologic specificity in the JAK\u2013STAT signaling pathway","volume":"84","author":"Meraz","year":"1996","journal-title":"Cell"},{"key":"10.1016\/j.cytogfr.2013.01.004_bib0205","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1126\/science.277.5332.1630","article-title":"STATs and gene regulation","volume":"277","author":"Darnell","year":"1997","journal-title":"Science"},{"key":"10.1016\/j.cytogfr.2013.01.004_bib0210","doi-asserted-by":"crossref","first-page":"171","DOI":"10.3322\/caac.20009","article-title":"Advances in understanding and management of myeloproliferative neoplasms","volume":"59","author":"Vannucchi","year":"2009","journal-title":"CA: A Cancer Journal for Clinicians"},{"key":"10.1016\/j.cytogfr.2013.01.004_bib0215","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1007\/s000180050394","article-title":"The role of STATs in proliferation, differentiation, and apoptosis","volume":"55","author":"Mui","year":"1999","journal-title":"Cellular and Molecular Life Sciences"},{"key":"10.1016\/j.cytogfr.2013.01.004_bib0220","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1126\/science.272.5262.719","article-title":"Cell growth arrest and induction of cyclin-dependent kinase inhibitor p21 WAF1\/CIP1 mediated by STAT1","volume":"272","author":"Chin","year":"1996","journal-title":"Science"},{"key":"10.1016\/j.cytogfr.2013.01.004_bib0225","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1016\/j.bcp.2011.12.024","article-title":"The many faces of Janus kinase","volume":"83","author":"Seavey","year":"2011","journal-title":"Biochemical Pharmacology"},{"key":"10.1016\/j.cytogfr.2013.01.004_bib0230","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1038\/sj.onc.1206158","article-title":"Delineating an oncostatin M-activated STAT3 signaling pathway that coordinates the expression of genes involved in cell cycle regulation and extracellular matrix deposition of MCF-7 cells","volume":"22","author":"Zhang","year":"2003","journal-title":"Oncogene"},{"key":"10.1016\/j.cytogfr.2013.01.004_bib0235","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1182\/blood-2002-07-2130","article-title":"Inhibition of STAT3 signaling induces apoptosis and decreases survivin expression in primary effusion lymphoma","volume":"101","author":"Aoki","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.cytogfr.2013.01.004_bib0240","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1038\/nrc2734","article-title":"STATs in cancer inflammation and immunity: a leading role for STAT3","volume":"9","author":"Yu","year":"2009","journal-title":"Nature Reviews Cancer"},{"key":"10.1016\/j.cytogfr.2013.01.004_bib0245","doi-asserted-by":"crossref","first-page":"3716","DOI":"10.1158\/1078-0432.CCR-07-4839","article-title":"Somatic mutations of JAK1 and JAK3 in acute leukemias and solid cancers","volume":"14","author":"Jeong","year":"2008","journal-title":"Clinical Cancer Research"},{"key":"10.1016\/j.cytogfr.2013.01.004_bib0250","doi-asserted-by":"crossref","DOI":"10.1038\/onc.2012.347","article-title":"JAK\/STAT signaling in hematological malignancies","author":"Vainchenker","year":"2012","journal-title":"Oncogene"},{"key":"10.1016\/j.cytogfr.2013.01.004_bib0255","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1038\/nature03546","article-title":"A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera","volume":"434","author":"James","year":"2005","journal-title":"Nature"},{"key":"10.1016\/j.cytogfr.2013.01.004_bib0260","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1056\/NEJMoa051113","article-title":"A gain-of-function mutation of JAK2 in myeloproliferative disorders","volume":"352","author":"Kralovics","year":"2005","journal-title":"New England Journal of Medicine"},{"key":"10.1016\/j.cytogfr.2013.01.004_bib0265","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1016\/S0140-6736(05)74230-6","article-title":"Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders","volume":"365","author":"Baxter","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.cytogfr.2013.01.004_bib0270","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.ccr.2005.03.023","article-title":"Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis","volume":"7","author":"Levine","year":"2005","journal-title":"Cancer Cell"},{"key":"10.1016\/j.cytogfr.2013.01.004_bib0275","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1182\/blood-2011-02-292102","article-title":"New mutations and pathogenesis of myeloproliferative neoplasms","volume":"188","author":"Vainchenker","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.cytogfr.2013.01.004_bib0280","doi-asserted-by":"crossref","first-page":"e270","DOI":"10.1371\/journal.pmed.0030270","article-title":"MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia","volume":"3","author":"Pikman","year":"2006","journal-title":"PLoS Medicine"},{"key":"10.1016\/j.cytogfr.2013.01.004_bib0285","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1182\/blood-2008-01-131664","article-title":"MPL mutations in myeloproliferative disorders: analysis of the PT-1 cohort","volume":"112","author":"Beer","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.cytogfr.2013.01.004_bib0290","doi-asserted-by":"crossref","first-page":"e33100","DOI":"10.1371\/journal.pone.0033100","article-title":"A highly sensitive quantitative real-time PCR assay for determination of mutant JAK2 exon 12 allele burden","volume":"7","author":"Kjaer","year":"2012","journal-title":"PLoS ONE"},{"key":"10.1016\/j.cytogfr.2013.01.004_bib0295","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1038\/ng.334","article-title":"JAK2 haplotype is a major risk factor for the development of myeloproliferative neoplasms","volume":"41","author":"Jones","year":"2009","journal-title":"Nature Genetics"},{"key":"10.1016\/j.cytogfr.2013.01.004_bib0300","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1038\/ng.341","article-title":"A common JAK2 haplotype confers susceptibility to myeloproliferative neoplasms","volume":"41","author":"Olcaydu","year":"2009","journal-title":"Nature Genetics"},{"key":"10.1016\/j.cytogfr.2013.01.004_bib0305","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1056\/NEJM200004273421706","article-title":"Myelofibrosis with myeloid metaplasia","volume":"342","author":"Tefferi","year":"2000","journal-title":"New England Journal of Medicine"},{"key":"10.1016\/j.cytogfr.2013.01.004_bib0310","doi-asserted-by":"crossref","first-page":"6735","DOI":"10.1158\/1078-0432.CCR-07-4843","article-title":"The interleukin-8 pathway in cancer","volume":"14","author":"Waugh","year":"2008","journal-title":"Clinical Cancer Research"},{"key":"10.1016\/j.cytogfr.2013.01.004_bib0315","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1016\/S0022-2143(99)90154-3","article-title":"Circulating levels of thrombopoietic and inflammatory cytokines in patients with clonal and reactive thrombocytosis","volume":"134","author":"Hsu","year":"1999","journal-title":"Journal of Laboratory and Clinical Medicine"},{"key":"10.1016\/j.cytogfr.2013.01.004_bib0320","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1111\/j.1365-2141.2005.05674.x","article-title":"Serum interleukin (IL)-1, IL-2, sIL-2Ra, IL-6 and thrombopoietin levels in patients with chronic myeloproliferative diseases","volume":"130","author":"Panteli","year":"2005","journal-title":"British Journal of Haematology"},{"key":"10.1016\/j.cytogfr.2013.01.004_bib0325","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1016\/j.leukres.2006.12.024","article-title":"Global cytokine analysis in myeloproliferative disorders","volume":"31","author":"Ho","year":"2007","journal-title":"Leukemia Research"},{"key":"10.1016\/j.cytogfr.2013.01.004_bib0330","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1038\/onc.2010.479","article-title":"Anti-inflammatory cytokines hepatocyte growth factor and interleukin-11 are over-expressed in polycythemia vera and contribute to the growth of clonal erythroblasts independently of JAK2V617F","volume":"30","author":"Boissinot","year":"2011","journal-title":"Oncogene"},{"key":"10.1016\/j.cytogfr.2013.01.004_bib0335","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1002\/ajh.21972","article-title":"Circulating levels of MCP-1, sIL-2R, IL-15, and IL-8 predict anemia response to pomalidomide therapy in myelofibrosis","volume":"86","author":"Pardanani","year":"2011","journal-title":"American Journal of Hematology"},{"key":"10.1016\/j.cytogfr.2013.01.004_bib0340","doi-asserted-by":"crossref","first-page":"1709","DOI":"10.1007\/s00432-010-0829-4","article-title":"Comparison of microarray-based RNA expression with ELISA-based protein determination of HER2, uPA and PAI-1 in tumour tissue of patients with breast cancer and relation to outcome","volume":"136","author":"Witzel","year":"2010","journal-title":"Journal of Cancer Research and Clinical Oncology"},{"key":"10.1016\/j.cytogfr.2013.01.004_bib0345","doi-asserted-by":"crossref","first-page":"3494","DOI":"10.1182\/blood-2010-11-315614","article-title":"How I treat myelofibrosis","volume":"117","author":"Tefferi","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.cytogfr.2013.01.004_bib0350","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1007\/s002770050595","article-title":"Dual implication of fibrogenic cytokines in the pathogenesis of fibrosis and myeloproliferation in myeloid metaplasia with myelofibrosis","volume":"78","author":"Le Bousse-Kerdiles","year":"1999","journal-title":"Annals of Hematology"},{"key":"10.1016\/j.cytogfr.2013.01.004_bib0355","doi-asserted-by":"crossref","first-page":"392","DOI":"10.2174\/138945011794815275","article-title":"Interferon alpha in the treatment of Philadelphia-negative chronic myeloproliferative neoplasms. Status and perspectives","volume":"12","author":"Hasselbalch","year":"2011","journal-title":"Current Drug Targets"},{"key":"10.1016\/j.cytogfr.2013.01.004_bib0360","doi-asserted-by":"crossref","first-page":"951","DOI":"10.2353\/ajpath.2008.071030","article-title":"Bone morphogenetic proteins are overexpressed in the bone marrow of primary myelofibrosis and are apparently induced by fibrogenic cytokines","volume":"172","author":"Bock","year":"2008","journal-title":"American Journal of Pathology"},{"key":"10.1016\/j.cytogfr.2013.01.004_bib0365","article-title":"Synergism between fibronectin and transforming growth factor-\u03b21 in the production of substance P in monocytes of patients with myelofibrosis","author":"Chang","year":"2012","journal-title":"Leukemia and Lymphoma"},{"key":"10.1016\/j.cytogfr.2013.01.004_bib0370","doi-asserted-by":"crossref","first-page":"1774","DOI":"10.1182\/blood-2012-02-402594","article-title":"Megakaryocyte pathology and bone marrow fibrosis: the lysyl oxidase connection","volume":"120","author":"Papadantonakis","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.cytogfr.2013.01.004_bib0375","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1096\/fj.11-193078","article-title":"Identification of oncostatin M as a JAK2 V617F-dependent amplifier of cytokine production and bone marrow remodeling in myeloproliferative neoplasms","volume":"26","author":"Hoermann","year":"2012","journal-title":"FASEB Journal"},{"key":"10.1016\/j.cytogfr.2013.01.004_bib0380","doi-asserted-by":"crossref","first-page":"3888","DOI":"10.1172\/JCI64397","article-title":"Spleens of myelofibrosis patients contain malignant hematopoietic stem cells","volume":"122","author":"Wang","year":"2012","journal-title":"J Clin Invest"},{"key":"10.1016\/j.cytogfr.2013.01.004_bib0385","doi-asserted-by":"crossref","first-page":"1760","DOI":"10.1016\/j.humpath.2007.04.004","article-title":"Janus kinase 2 V617F mutation is detectable in spleen of patients with chronic myeloproliferative diseases suggesting a malignant nature of splenic extramedullary hematopoiesis","volume":"38","author":"Konoplev","year":"2007","journal-title":"Human Pathology"},{"key":"10.1016\/j.cytogfr.2013.01.004_bib0390","doi-asserted-by":"crossref","first-page":"3283","DOI":"10.1172\/JCI31772","article-title":"TNF-\u03b1 induces leukemic clonal evolution ex vivo in Fanconi anemia group C murine stem cells","volume":"117","author":"Li","year":"2007","journal-title":"Journal of Clinical Investigation"},{"key":"10.1016\/j.cytogfr.2013.01.004_bib0395","doi-asserted-by":"crossref","first-page":"6392","DOI":"10.1182\/blood-2011-04-348144","article-title":"TNF\u03b1 facilitates clonal expansion of JAK2V617F positive cells in myeloproliferative neoplasms","volume":"118","author":"Fleischman","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.cytogfr.2013.01.004_bib0400","doi-asserted-by":"crossref","first-page":"1988","DOI":"10.1158\/1078-0432.CCR-09-2836","article-title":"Therapeutic potential of Janus-activated kinase-2 inhibitors for the management of myelofibrosis","volume":"16","author":"Verstovsek","year":"2010","journal-title":"Clinical Cancer Research"},{"key":"10.1016\/j.cytogfr.2013.01.004_bib0405","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.3324\/haematol.2009.020412","article-title":"Autoimmunity and the risk of myeloproliferative neoplasms","volume":"95","author":"Kristinsson","year":"2010","journal-title":"Haematologica"},{"key":"10.1016\/j.cytogfr.2013.01.004_bib0410","doi-asserted-by":"crossref","first-page":"2068","DOI":"10.1158\/1055-9965.EPI-09-0353","article-title":"Increased risk of lymphoid neoplasms in patients with Philadelphia chromosome-negative myeloproliferative neoplasms","volume":"18","author":"Vannucchi","year":"2009","journal-title":"Cancer Epidemiology, Biomarkers and Prevention"},{"key":"10.1016\/j.cytogfr.2013.01.004_bib0415","doi-asserted-by":"crossref","first-page":"6515","DOI":"10.1182\/blood-2011-04-348755","article-title":"Chronic myeloproliferative neoplasms and subsequent cancer risk: a Danish population-based cohort study","volume":"118","author":"Frederiksen","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.cytogfr.2013.01.004_bib0420","doi-asserted-by":"crossref","first-page":"3861","DOI":"10.1182\/blood-2011-12-401455","article-title":"Risk of second cancers in chronic myeloproliferative neoplasms","volume":"119","author":"Susini","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.cytogfr.2013.01.004_bib0425","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.3324\/haematol.2011.055392","article-title":"The JAK2 46\/1 haplotype: a marker of inappropriate myelomonocytic response to cytokine stimulation, leading to increased risk of inflammation, myeloid neoplasm, and impaired defense against infection?","volume":"96","author":"Hermouet","year":"2011","journal-title":"Haematologica"},{"key":"10.1016\/j.cytogfr.2013.01.004_bib0430","doi-asserted-by":"crossref","first-page":"450","DOI":"10.3324\/haematol.2010.033191","article-title":"The JAK2 V617F somatic mutation, mortality and cancer risk in the general population","volume":"96","author":"Nielsen","year":"2011","journal-title":"Haematologica"},{"key":"10.1016\/j.cytogfr.2013.01.004_bib0435","doi-asserted-by":"crossref","first-page":"4589","DOI":"10.1182\/blood-2005-10-4169","article-title":"Role of transforming growth factor-\u03b2 in hematologic malignancies","volume":"107","author":"Dong","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.cytogfr.2013.01.004_bib0440","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1517\/14712598.7.4.449","article-title":"Vascular endothelial growth factor and immunosuppression in cancer: current knowledge and potential for new therapy","volume":"7","author":"Johnson","year":"2007","journal-title":"Expert Opinion on Biological Therapy"},{"key":"10.1016\/j.cytogfr.2013.01.004_bib0445","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/j.it.2010.04.002","article-title":"TGF-beta and immune cells: an important regulatory axis in the tumor microenvironment and progression","volume":"31","author":"Yang","year":"2010","journal-title":"Trends in Immunology"},{"key":"10.1016\/j.cytogfr.2013.01.004_bib0450","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1182\/blood-2008-01-134114","article-title":"JAK2 stimulates homologous recombination and genetic instability: potential implication in the heterogeneity of myeloproliferative disorders","volume":"112","author":"Plo","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.cytogfr.2013.01.004_bib0455","doi-asserted-by":"crossref","first-page":"6468","DOI":"10.1182\/blood-2011-08-372813","article-title":"Homologous recombination of wild-type JAK2, a novel early step in the development of myeloproliferative neoplasm","volume":"118","author":"Vilaine","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.cytogfr.2013.01.004_bib0460","doi-asserted-by":"crossref","first-page":"2224","DOI":"10.1200\/JCO.2005.07.062","article-title":"Vascular and neoplastic risk in a large cohort of patients with polycythemia vera","volume":"23","author":"Marchioli","year":"2005","journal-title":"Journal of Clinical Oncology"},{"issue":"10","key":"10.1016\/j.cytogfr.2013.01.004_bib0465","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1517\/14656566.2011.568939","article-title":"Therapeutic approaches in myelofibrosis","volume":"12","author":"Barosi","year":"2011","journal-title":"Expert Opinion on Pharmacotherapy"},{"key":"10.1016\/j.cytogfr.2013.01.004_bib0470","doi-asserted-by":"crossref","first-page":"3572","DOI":"10.1182\/blood-2009-12-260588","article-title":"Impact of JAK2V617F mutation status, allele burden, and clearance after allogeneic stem cell transplantation for myelofibrosis","volume":"116","author":"Alchalby","year":"2010","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.cytogfr.2013.01.004_bib0475","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1182\/blood-2012-05-399048","article-title":"Allogeneic hematopoietic cell transplantation for myelofibrosis in the era of JAK inhibitors","volume":"120","author":"Gupta","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.cytogfr.2013.01.004_bib0480","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/S0140-6736(88)92881-4","article-title":"Recombinant interferon-alpha for treatment of polycythaemia vera","volume":"2","author":"Silver","year":"1988","journal-title":"Lancet"},{"key":"10.1016\/j.cytogfr.2013.01.004_bib0485","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1016\/S0140-6736(88)92625-6","article-title":"Treatment of essential thrombocythaemia by alpha 2a interferon","volume":"2","author":"Bellucci","year":"1988","journal-title":"Lancet"},{"key":"10.1016\/j.cytogfr.2013.01.004_bib0490","first-page":"123","article-title":"Therapy with interferon (recombinant IFN-alpha-2C) in myeloproliferative diseases with severe thrombocytoses","volume":"12","author":"Linkesch","year":"1985","journal-title":"Acta Medica Austriaca"},{"key":"10.1016\/j.cytogfr.2013.01.004_bib0495","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1002\/cncr.22026","article-title":"Long-term effects of the treatment of polycythemia vera with recombinant interferon-\u03b1","volume":"107","author":"Silver","year":"2006","journal-title":"Cancer"},{"key":"10.1016\/j.cytogfr.2013.01.004_bib0500","doi-asserted-by":"crossref","first-page":"2397","DOI":"10.1002\/cncr.21900","article-title":"A phase II trial of pegylated interferon \u03b1-2b therapy for polycythemia vera and essential thrombocythemia: feasibility, clinical and biologic effects, and impact on quality of life","volume":"106","author":"Samuelsson","year":"2006","journal-title":"Cancer"},{"key":"10.1016\/j.cytogfr.2013.01.004_bib0505","doi-asserted-by":"crossref","first-page":"2037","DOI":"10.1182\/blood-2006-03-009860","article-title":"High molecular response rate of polycythemia vera patients treated with pegylated interferon \u03b1-2a","volume":"108","author":"Kiladjian","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.cytogfr.2013.01.004_bib0510","doi-asserted-by":"crossref","first-page":"3065","DOI":"10.1182\/blood-2008-03-143537","article-title":"Pegylated interferon-alfa-2a induces complete hematologic and molecular responses with low toxicity in polycythemia vera","volume":"112","author":"Kiladjian","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.cytogfr.2013.01.004_bib0515","doi-asserted-by":"crossref","first-page":"5418","DOI":"10.1200\/JCO.2009.23.6075","article-title":"Pegylated interferon alfa-2a yields high rates of hematologic and molecular response in patients with advanced essential thrombocythemia and polycythemia vera","volume":"27","author":"Quint\u00e1s-Cardama","year":"2009","journal-title":"Journal of Clinical Oncology"},{"key":"10.1016\/j.cytogfr.2013.01.004_bib0520","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1179\/102453309X12473408860587","article-title":"Minimal residual disease and normalization of the bone marrow after long-term treatment with alpha-interferon2b in polycythemia vera. A report on molecular response patterns in seven patients in sustained complete hematological remission","volume":"14","author":"Larsen","year":"2009","journal-title":"Hematology"},{"key":"10.1016\/j.cytogfr.2013.01.004_bib0525","first-page":"118","article-title":"Complete hematological, molecular and histological remissions without cytoreductive treatment lasting after pegylated-interferon \u03b1-2a (peg-IFN\u03b1-2a) therapy in polycythemia vera (PV): long term results of a phase 2 trial","author":"Turlure","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.cytogfr.2013.01.004_bib0530","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1038\/leu.2009.90","article-title":"Recombinant interferon alpha (rIFN \u03b1-2b) may retard progression of early primary myelofibrosis","volume":"23","author":"Silver","year":"2009","journal-title":"Leukemia"},{"key":"10.1016\/j.cytogfr.2013.01.004_bib0535","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1111\/j.1365-2141.2009.07745.x","article-title":"PEG-IFN-\u03b1-2a therapy in patients with myelofibrosis: a study of the French Groupe d\u2019Etudes des Myelofibroses (GEM) and France Intergroupe des syndromes Myeloproliferatifs (FIM)","volume":"146","author":"Ianotto","year":"2009","journal-title":"British Journal of Haematology"},{"key":"10.1016\/j.cytogfr.2013.01.004_bib0540","doi-asserted-by":"crossref","first-page":"6669","DOI":"10.1182\/blood-2010-11-320069","article-title":"Recombinant interferon-\u03b1 may retard progression of early primary myelofibrosis: a preliminary report","volume":"117","author":"Silver","year":"2011","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.cytogfr.2013.01.004_bib0545","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.3324\/haematol.2011.061390","article-title":"Experience with pegylated interferon \u03b1-2a in advanced myeloproliferative neoplasms in an international cohort of 118 patients","volume":"97","author":"Gowin","year":"2012","journal-title":"Haematologica"},{"key":"10.1016\/j.cytogfr.2013.01.004_bib0550","doi-asserted-by":"crossref","first-page":"1990","DOI":"10.1038\/leu.2008.280","article-title":"Interferon-\u03b1 therapy in bcr-abl-negative myeloproliferative neoplasms","volume":"22","author":"Kiladjian","year":"2008","journal-title":"Leukemia"},{"key":"10.1016\/j.cytogfr.2013.01.004_bib0555","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1586\/ehm.11.63","article-title":"A new era for IFN-\u03b1 in the treatment of Philadelphia-negative chronic myeloproliferative neoplasms","volume":"4","author":"Hasselbalch","year":"2011","journal-title":"Expert Review of Hematology"},{"key":"10.1016\/j.cytogfr.2013.01.004_bib0560","doi-asserted-by":"crossref","first-page":"4706","DOI":"10.1182\/blood-2010-08-258772","article-title":"The renaissance of interferon therapy for the treatment of myeloid malignancies","volume":"117","author":"Kiladjian","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.cytogfr.2013.01.004_bib0565","unstructured":"Silver RT, Kiladjian JJ, Hasselbalch HC. Interferon and the treatment of essential thrombocythemia, polycythemia vera and myelofibrosis. Expert Review of Hematology; in press."},{"key":"10.1016\/j.cytogfr.2013.01.004_bib0570","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1182\/blood.V70.4.1014.1014","article-title":"Effects of recombinant \u03b1 and \u03b3 interferons on the in vitro growth of circulating hematopoietic progenitor cells (CFU-GEMM, CFU-Mk, BFU-E, and CFU-GM) from patients with myelofibrosis with myeloid metaplasia","volume":"70","author":"Carlo-Stella","year":"1987","journal-title":"Blood"},{"key":"10.1016\/j.cytogfr.2013.01.004_bib0575","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1111\/j.1365-2141.1994.tb08324.x","article-title":"The in vitro and in vivo effect of recombinant interferon alpha-2a on circulating haemopoietic progenitors in polycythaemia vera","volume":"87","author":"Castello","year":"1994","journal-title":"British Journal of Haematology"},{"key":"10.1016\/j.cytogfr.2013.01.004_bib0580","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1182\/blood.V96.6.2093","article-title":"Interferon-\u03b1 directly represses megakaryopoiesis by inhibiting thrombopoietin-induced signaling through induction of SOCS-1","volume":"96","author":"Wang","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.cytogfr.2013.01.004_bib0585","doi-asserted-by":"crossref","first-page":"55","DOI":"10.3109\/10428199609054802","article-title":"Interferon-alpha and its effects on the cytokine cascade: a pro- and anti-inflammatory cytokine","volume":"23","author":"Tilg","year":"1996","journal-title":"Leukemia and Lymphoma"},{"key":"10.1016\/j.cytogfr.2013.01.004_bib0590","doi-asserted-by":"crossref","first-page":"4687","DOI":"10.4049\/jimmunol.150.10.4687","article-title":"Induction of circulating IL-1 receptor antagonist by IFN treatment","volume":"150","author":"Tilg","year":"1993","journal-title":"Journal of Immunology"},{"key":"10.1016\/j.cytogfr.2013.01.004_bib0595","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1089\/jir.1995.15.317","article-title":"Type 1 interferon as an antiinflammatory agent: inhibition of lipopolysaccharide-induced interleukin-1 beta and induction of interleukin-1 receptor antagonist","volume":"15","author":"Huang","year":"1995","journal-title":"Journal of Interferon and Cytokine Research"},{"key":"10.1016\/j.cytogfr.2013.01.004_bib0600","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1007\/BF01715048","article-title":"Divergent in vivo and in vitro antileukemic activity of recombinant interferon beta in patients with chronic-phase chronic myelogenous leukemia","volume":"67","author":"Aulitzky","year":"1993","journal-title":"Annals of Hematology"},{"key":"10.1016\/j.cytogfr.2013.01.004_bib0605","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1002\/eji.201141550","article-title":"A clinical perspective of IL-1\u03b2 as the gatekeeper of inflammation","volume":"41","author":"Dinarello","year":"2011","journal-title":"European Journal of Immunology"},{"key":"10.1016\/j.cytogfr.2013.01.004_bib0610","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.lab.2003.09.006","article-title":"Interleukin-1\u03b2 up-regulates the expression of thrombopoietin and transcription factors c-Jun, c-Fos, GATA-1, and NF-E2 in megakaryocytic cells","volume":"143","author":"Chuen","year":"2004","journal-title":"Journal of Laboratory and Clinical Medicine"},{"key":"10.1016\/j.cytogfr.2013.01.004_bib0615","doi-asserted-by":"crossref","first-page":"9049","DOI":"10.1073\/pnas.89.19.9049","article-title":"Downregulation of interleukin 8 gene expression in human fibroblasts: unique mechanism of transcriptional inhibition by interferon","volume":"89","author":"Oliveira","year":"1992","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"10.1016\/j.cytogfr.2013.01.004_bib0620","doi-asserted-by":"crossref","first-page":"2371","DOI":"10.1182\/blood.V82.8.2371.2371","article-title":"Type-I interferons are potent inhibitors of interleukin-8 production in hematopoietic and bone marrow stromal cells","volume":"82","author":"Aman","year":"1993","journal-title":"Blood"},{"key":"10.1016\/j.cytogfr.2013.01.004_bib0625","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1517\/13543784.2011.538382","article-title":"Janus kinase 2 inhibitors in myeloproliferative disorders","volume":"20","author":"Lucia","year":"2011","journal-title":"Expert Opinion on Investigational Drugs"},{"key":"10.1016\/j.cytogfr.2013.01.004_bib0630","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1056\/NEJMoa1110557","article-title":"A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis","volume":"366","author":"Verstovsek","year":"2012","journal-title":"New England Journal of Medicine"},{"key":"10.1016\/j.cytogfr.2013.01.004_bib0635","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1056\/NEJMoa1110556","article-title":"JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis","volume":"366","author":"Harrison","year":"2012","journal-title":"New England Journal of Medicine"},{"issue":"s1","key":"10.1016\/j.cytogfr.2013.01.004_bib0640","article-title":"Association of cytokine levels and reductions in spleen size in COMFORT-II: a phase 3 study comparing ruxolitinib with best available therapy (BAT)","volume":"97","author":"Harrison","year":"2012","journal-title":"Haematologica"},{"key":"10.1016\/j.cytogfr.2013.01.004_bib0645","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1056\/NEJMoa1002028","article-title":"Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis","volume":"363","author":"Verstovsek","year":"2010","journal-title":"New England Journal of Medicine"},{"key":"10.1016\/j.cytogfr.2013.01.004_bib0650","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1182\/blood-2012-02-414631","article-title":"Long-term outcomes of 107 patients with myelofibrosis receiving JAK1\/JAK2 inhibitor ruxolitinib: survival advantage in comparison to matched historical controls","volume":"120","author":"Verstovsek","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.cytogfr.2013.01.004_bib0655","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1200\/JCO.2010.32.8021","article-title":"Safety and efficacy of TG101348, a selective JAK2 inhibitor, in myelofibrosis","volume":"29","author":"Pardanani","year":"2011","journal-title":"Journal of Clinical Oncology"},{"key":"10.1016\/j.cytogfr.2013.01.004_bib0660","first-page":"118","article-title":"A phase II randomized dose-ranging study of the JAK2-selective inhibitor SAR302503 in patients with intermediate-2 or high-risk primary myelofibrosis (MF), post-polycythemia vera (PV) MF, or post-essential thrombocythemia (ET) MF","author":"Talpaz","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.cytogfr.2013.01.004_bib0665","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1182\/blood-2009-10-246363","article-title":"Phase 2 study of CEP-701, an orally available JAK2 inhibitor, in patients with primary or post-polycythemia vera\/essential thrombocythemia myelofibrosis","volume":"115","author":"Santos","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.cytogfr.2013.01.004_bib0670","doi-asserted-by":"crossref","first-page":"5232","DOI":"10.1182\/blood-2009-05-223727","article-title":"CYT387, a novel JAK2 inhibitor, induces hematologic responses and normalizes inflammatory cytokines in murine myeloproliferative neoplasms","volume":"115","author":"Tyner","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.cytogfr.2013.01.004_bib0675","first-page":"119","article-title":"SAR302503: interim safety, efficacy and long-term impact on JAK2 V617F allele burden in a phase I\/II study in patients with myelofibrosis","author":"Pardanani","year":"2011","journal-title":"Blood"},{"issue":"s1","key":"10.1016\/j.cytogfr.2013.01.004_bib0680","first-page":"151","article-title":"Reductions in JAK2 V617F allele burden with ruxolitinib treatment in COMFORT-II, a phase 3 study comparing the safety and efficacy of ruxolitinib to best available therapy (BAT)","volume":"97","author":"Vannucchi","year":"2012","journal-title":"Haematologica"},{"key":"10.1016\/j.cytogfr.2013.01.004_bib0685","first-page":"5","article-title":"Myelofibrosis: molecular and cell biological aspects","author":"Kreipe","year":"2012","journal-title":"Fibrogenesis and Tissue Repair"},{"key":"10.1016\/j.cytogfr.2013.01.004_bib0690","first-page":"5","article-title":"Primary myelofibrosis and the \u201cbad seeds in bad soil\u201d concept","author":"Le Bousse-Kerdiles","year":"2012","journal-title":"Fibrogenesis and Tissue Repair"},{"key":"10.1016\/j.cytogfr.2013.01.004_bib0695","doi-asserted-by":"crossref","first-page":"3026","DOI":"10.1182\/blood-2008-06-158386","article-title":"Does primary myelofibrosis involve a defective stem cell niche? From concept to evidence","volume":"112","author":"Lataillade","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.cytogfr.2013.01.004_bib0700","doi-asserted-by":"crossref","first-page":"3831","DOI":"10.1158\/0008-5472.CAN-10-4002","article-title":"Bone marrow stroma-secreted cytokines protect JAK2(V617F)-mutated cells from the effects of a JAK2 inhibitor","volume":"71","author":"Manshouri","year":"2011","journal-title":"Cancer Research"},{"key":"10.1016\/j.cytogfr.2013.01.004_bib0705","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1038\/leu.2008.299","article-title":"CXCR4 antagonists: targeting the microenvironment in leukemia and other cancers","volume":"23","author":"Burger","year":"2009","journal-title":"Leukemia"},{"issue":"6","key":"10.1016\/j.cytogfr.2013.01.004_bib0710","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1097\/CCO.0b013e3283589950","article-title":"Targeting the microenvironment in chronic lymphocytic leukemia is changing the therapeutic landscape","volume":"24","author":"Burger","year":"2012","journal-title":"Current Opinion in Oncology"},{"key":"10.1016\/j.cytogfr.2013.01.004_bib0715","doi-asserted-by":"crossref","first-page":"3367","DOI":"10.1182\/blood-2009-06-225326","article-title":"The microenvironment in mature B-cell malignancies: a target for new treatment strategies","volume":"114","author":"Burger","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.cytogfr.2013.01.004_bib0720","doi-asserted-by":"crossref","first-page":"2233","DOI":"10.1038\/leu.2009.175","article-title":"Contribution of bone microenvironment to leukemogenesis and leukemia progression","volume":"23","author":"Ayala","year":"2009","journal-title":"Leukemia"},{"key":"10.1016\/j.cytogfr.2013.01.004_bib0725","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1038\/nature07815","article-title":"IFN\u03b1 activates dormant haematopoietic stem cells in vivo","volume":"458","author":"Essers","year":"2009","journal-title":"Nature"},{"key":"10.1016\/j.cytogfr.2013.01.004_bib0730","doi-asserted-by":"crossref","first-page":"2170","DOI":"10.1182\/blood-2011-03-340992","article-title":"Increase in circulating CD4(+)CD25(+)Foxp3(+) T cells in patients with Philadelphia-negative chronic myeloproliferative neoplasms during treatment with IFN-alpha","volume":"118","author":"Riley","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.cytogfr.2013.01.004_bib0735","first-page":"807","article-title":"Salutary effect of pegylated interferon-a in PV and ET as evaluated by quantitation of Pre-JAK2V617F and JAK2V617F-bearing stem cells and granulocytes and correlation with circulating regulatory T Cells and HSC cell cycle status","volume":"120","author":"Swierczek","year":"2012","journal-title":"ASH Annual Meeting Abstracts"},{"key":"10.1016\/j.cytogfr.2013.01.004_bib0740","doi-asserted-by":"crossref","first-page":"421702","DOI":"10.1155\/2012\/421702","article-title":"Hematological malignancies escape from NK cell innate immune surveillance: mechanisms and therapeutic implications","volume":"2012","author":"Farnault","year":"2012","journal-title":"Clinical and Developmental Immunology"},{"key":"10.1016\/j.cytogfr.2013.01.004_bib0745","first-page":"136","article-title":"Quantitative and functional studies of impaired natural killer (NK) cells in patients with myelofibrosis, essential thrombocythemia, and polycythemia vera. I. A potential role for platelet-derived growth factor in defective NK cytotoxicity","volume":"12","author":"Gersuk","year":"1993","journal-title":"Natural Immunity"},{"key":"10.1016\/j.cytogfr.2013.01.004_bib0750","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1038\/nm1325","article-title":"Inhibiting Stat3 signaling in the hematopoietic system elicits multicomponent antitumor immunity","volume":"11","author":"Kortylewski","year":"2005","journal-title":"Nature Medicine"},{"key":"10.1016\/j.cytogfr.2013.01.004_bib0755","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.1158\/1078-0432.CCR-06-1387","article-title":"Modulation of signal transducers and activators of transcription 1 and 3 signaling in melanoma by high-dose IFN\u03b12b","volume":"13","author":"Wang","year":"2007","journal-title":"Clinical Cancer Research"},{"key":"10.1016\/j.cytogfr.2013.01.004_bib0760","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1002\/jcb.22185","article-title":"Histone deacetylase inhibitors: potential in cancer therapy","volume":"107","author":"Marks","year":"2009","journal-title":"Journal of Cellular Biochemistry"},{"key":"10.1016\/j.cytogfr.2013.01.004_bib0765","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1038\/nrd2133","article-title":"Anticancer activities of histone deacetylase inhibitors","volume":"5","author":"Bolden","year":"2006","journal-title":"Nature Reviews Drug Discovery"},{"key":"10.1016\/j.cytogfr.2013.01.004_bib0770","doi-asserted-by":"crossref","first-page":"601","DOI":"10.2217\/fon.09.36","article-title":"Panobinostat (LBH589): a potent pan-deacetylase inhibitor with promising activity against hematologic and solid tumors","volume":"5","author":"Prince","year":"2009","journal-title":"Future Oncology"},{"key":"10.1016\/j.cytogfr.2013.01.004_bib0775","doi-asserted-by":"crossref","first-page":"4500","DOI":"10.1158\/1078-0432.CCR-07-4262","article-title":"Histone deacetylase inhibitor panobinostat induces clinical responses with associated alterations in gene expression profiles in cutaneous T-cell lymphoma","volume":"14","author":"Ellis","year":"2008","journal-title":"Clinical Cancer Research"},{"key":"10.1016\/j.cytogfr.2013.01.004_bib0780","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1111\/j.1365-2141.2009.07837.x","article-title":"Preliminary evidence of disease response to the pan deacetylase inhibitor panobinostat (LBH589) in refractory Hodgkin Lymphoma","volume":"147","author":"Dickinson","year":"2009","journal-title":"British Journal of Haematology"},{"key":"10.1016\/j.cytogfr.2013.01.004_bib0790","first-page":"116","article-title":"A phase II trial of panobinostat, an orally available deacetylase inhibitor, in patients with primary myelofibrosis, post-essential thrombocythemia myelofibrosis, and post-polycythemia vera myelofibrosis","author":"DeAngelo","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.cytogfr.2013.01.004_bib0785","first-page":"118","article-title":"Improved efficacy upon combined JAK1\/2 and pan-deacetylase inhibition using ruxolitinib (INC424) and panobinostat (LBH589) in preclinical mouse models of JAK2 V617F-driven disease","author":"Baffert","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.cytogfr.2013.01.004_bib0795","doi-asserted-by":"crossref","first-page":"e69","DOI":"10.1038\/bcj.2012.14","article-title":"The oral HDAC inhibitor pracinostat (SB939) is efficacious and synergistic with the JAK2 inhibitor pacritinib (SB1518) in preclinical models of AML","volume":"2","author":"Novotny-Diermayr","year":"2012","journal-title":"Blood Cancer Journal"},{"key":"10.1016\/j.cytogfr.2013.01.004_bib0800","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1016\/j.leukres.2005.12.018","article-title":"Statins in the treatment of polycythaemia vera and allied disorders: an antithrombotic and cytoreductive potential?","volume":"30","author":"Hasselbalch","year":"2006","journal-title":"Leukemia Research"},{"key":"10.1016\/j.cytogfr.2013.01.004_bib0805","first-page":"118","article-title":"A mechanistic rationale for the use of statins to enhance JAK Inhibitor therapy in MPNs","author":"Griner","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.cytogfr.2013.01.004_bib0810","article-title":"JAK2-V617F-mediated signalling is dependent on lipid rafts and statins inhibit JAK2-V617F-dependent cell growth","author":"Griner","year":"2012","journal-title":"British Journal of Haematology"},{"key":"10.1016\/j.cytogfr.2013.01.004_bib0815","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.leukres.2008.06.002","article-title":"Myelofibrosis with myeloid metaplasia: the advanced phase of an untreated disseminated hematological cancer. Time to change our therapeutic attitude with early upfront treatment?","volume":"33","author":"Hasselbalch","year":"2009","journal-title":"Leukemia Research"},{"key":"10.1016\/j.cytogfr.2013.01.004_bib0820","doi-asserted-by":"crossref","first-page":"e564","DOI":"10.1200\/JCO.2011.35.6238","article-title":"Interferon alfa in the treatment of Philadelphia-negative chronic myeloproliferative neoplasms","volume":"29","author":"Hasselbalch","year":"2011","journal-title":"Journal of Clinical Oncology"},{"issue":"5","key":"10.1016\/j.cytogfr.2013.01.004_bib0825","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1200\/JCO.2010.29.8711","article-title":"Myeloproliferative neoplasms: molecular pathophysiology, essential clinical understanding, and treatment strategies","volume":"29","author":"Tefferi","year":"2011","journal-title":"J Clin Oncol."},{"key":"10.1016\/j.cytogfr.2013.01.004_bib0855","article-title":"Inflammation and clone evolution in myeloproliferative neoplasms: Interest of combining drugs that target key cytokines with different signaling pathways","author":"Hermouet","year":"2012","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.cytogfr.2013.01.004_bib0830","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1002\/cncr.22365","article-title":"The burden of fatigue and quality of life in myeloproliferative disorders MPDs): an international Internet-based survey of 1179 MPD patients","volume":"109","author":"Mesa","year":"2007","journal-title":"Cancer"},{"issue":"9","key":"10.1016\/j.cytogfr.2013.01.004_bib0835","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1016\/j.leukres.2009.01.035","article-title":"The Myelofibrosis Symptom Assessment Form (MFSAF): an evidence-based brief inventory to measure quality of life and symptomatic response to treatment in myelofibrosis","volume":"33","author":"Mesa","year":"2009","journal-title":"Leukemia Research"},{"issue":"2","key":"10.1016\/j.cytogfr.2013.01.004_bib0840","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1182\/blood-2011-01-328955","article-title":"The Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF): international prospective validation and reliability trial in 402 patients","volume":"118","author":"Scherber","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.cytogfr.2013.01.004_bib0845","doi-asserted-by":"crossref","first-page":"441","DOI":"10.3109\/10428194.2011.619608","article-title":"Association between quality of life and clinical parameters in patients with myeloproliferative neoplasms","volume":"53","author":"Johansson","year":"2012","journal-title":"Leukemia and Lymphoma"},{"key":"10.1016\/j.cytogfr.2013.01.004_bib0850","doi-asserted-by":"crossref","first-page":"4098","DOI":"10.1200\/JCO.2012.42.3863","article-title":"Myeloproliferative neoplasm (MPN) symptom assessment form total symptom score: prospective international assessment of an abbreviated symptom burden scoring system among patients with MPNs","volume":"33","author":"Emanuel","year":"2012","journal-title":"Journal of Clinical Oncology"}],"container-title":["Cytokine & Growth Factor Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1359610113000051?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1359610113000051?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,6,29]],"date-time":"2023-06-29T14:16:13Z","timestamp":1688048173000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1359610113000051"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,4]]},"references-count":171,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2013,4]]}},"alternative-id":["S1359610113000051"],"URL":"https:\/\/doi.org\/10.1016\/j.cytogfr.2013.01.004","relation":{},"ISSN":["1359-6101"],"issn-type":[{"value":"1359-6101","type":"print"}],"subject":[],"published":{"date-parts":[[2013,4]]}}}